

HEPATOBIILIARY DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
ROOM: CHURCHILL "B"

SATURDAY APRIL 26TH, 2025 11:15 AM – 12:00 PM

CO-CHAIRS : DR PAUL KARNICOLAS & DR VINCENT TAM
SENIOR INVESTIGATOR: DR CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with hepatobiliary malignancies in Canada.
- To identify clinical trial research opportunities in hepatobiliary malignancies within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to hepatobiliary malignancies.
- To integrate and apply new clinical trial methodologies in hepatobiliary malignancies in the Canadian Cancer Trials Group research agenda.
- To identify mentoring opportunities for new investigators.

11:15 am	Welcome	
11:15 am	HE.2 (SLIDE-HCC): Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable Hepatocellular Carcinoma	Dr V Tam Dr J Knox
11:30 am	Son of HE.1: Single fraction risk-adapted radiotherapy for treatment refractory or end stage liver cancer: A Phase III Randomized Control Trial	Dr M Yan Dr L Dawson
11:40 am	AGITG BIL-PPP: PD1 and PARP inhibitor as maintenance treatment following platinum-gemcitabine for unresectable locally-advanced or metastatic biliary tract cancers	Dr C Karapetis
11:10 am	NCTN Hepatobiliary Task Force Update	Dr V Tam & Dr P Karanicolas
12:00 pm	Meeting Adjourned	

